EHBP1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the endocytic adaptor protein EHBP1 in a human haploid cellular background. This product is generated by introducing CRISPR/Cas9-mediated gene disruption into the HAP1 cell line, yielding a heterogeneous pool of edited cells that collectively ablate EHBP1 expression. Unlike monoclonal lines, this polyclonal population captures allelic diversity and is particularly suited for pooled genetic screens and functional assays where clonal variation needs to be averaged out. The knockout model enables robust investigation of EHBP1-dependent phenotypes without selective pressures associated with single-cell cloning, thereby preserving biological complexity while providing a reliable tool for dissecting endocytic trafficking and actin cytoskeleton regulation.
The host cell model is derived from the HAP1 cell line, a near-haploid chronic myeloid leukemia (CML) line that has become a cornerstone of functional genomics due to its stable haploid karyotype. The reduced genome complexity facilitates efficient CRISPR/Cas9 editing and simplifies interpretation of knockout phenotypes by minimizing confounding effects from diploid allele compensation. HAP1 cells retain key signaling pathways relevant to hematological malignancies and receptor-mediated processes, making them an ideal chassis for studying cancer-related genes. Their adherent growth and compatibility with standard cell culture techniques further enhance their utility in high-content imaging, biochemical, and migration-based experiments.
At the molecular level, EHBP1 functions as a scaffolding adaptor that bridges EH domain-containing proteins, such as EPS15, to the actin cytoskeleton via direct binding to ??-actin (ACTB). This interaction is critical for coupling receptor internalization to actin remodeling, a process activated by epidermal growth factor (EGF) through the epidermal growth factor receptor (EGFR). EHBP1 operates within the EGFR-EPS15-EHBP1-actin signaling axis, where it integrates signals from upstream growth factors to coordinate the formation of endocytic vesicles and the reorganization of actin filaments. Additional interacting partners include intersectin-1 (ITSN1) and various RAB GTPases, which together regulate membrane scission and vesicle trafficking. Downstream targets encompass actin filaments, endocytic vesicles, and cell adhesion molecules, positioning EHBP1 at the nexus of endocytosis and cell migration. The protein??s involvement in these dynamic processes underscores its relevance to pathologies characterized by aberrant cell motility, such as cancer metastasis and atherosclerosis, as well as neurological disorders where membrane trafficking is disrupted.
In the HAP1 context, EHBP1 knockout permits precise dissection of endocytic and migratory mechanisms often dysregulated in CML and other cancers. The near-haploid background eliminates the complexity of heterozygous mutations, allowing clearer phenotypic assignment to EHBP1 loss. This model is particularly valuable for exploring how the EGFR-EPS15-EHBP1-actin axis contributes to receptor-mediated endocytosis and directed cell movement. Given HAP1??s origins from a leukemic lineage, the knockout system also offers a platform to investigate the role of EHBP1 in hematological tumorigenesis and drug resistance, where actin dynamics and endosomal sorting may influence therapeutic responses. The polyclonal nature of the cells further supports pooled screening strategies to identify genetic interactors or chemical modulators of EHBP1 function.
Researchers can employ EHBP1 Knockout HAP1 Polyclonal Cells in a wide array of experimental paradigms. Western blotting confirms EHBP1 depletion, while immunofluorescence enables visualization of actin disorganization and altered endocytic vesicle distribution. Quantitative migration and invasion assays, such as transwell or scratch wound assays, directly assess the impact on cell motility. Endocytosis efficiency can be measured using transferrin uptake assays, and co-immunoprecipitation experiments validate the loss of EHBP1-EPS15 complex formation. These applications make the knockout cells a powerful resource for cancer cell migration studies, drug resistance screening, and functional genomics. For additional technical details, please contact Ascent Research.
